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Abstract
Background: A major problem with the use of current chemotherapy regimens for several cancers, including
breast cancer, is development of intrinsic or acquired drug resistance, which results in disease recurrence and
metastasis. However, the mechanisms underlying this drug resistance are unknown. To study the molecular
mechanisms underlying the invasive and metastatic activities of drug-resistant cancer cells, we generated a
doxorubicin-resistant MCF-7 breast cancer cell line (MCF-7/DOX).
Methods: We used MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays, flow cytometry assays,
DNA fragmentation assays, Western blot analysis, cell invasion assays, small interfering RNA (siRNA) transfection,
reverse transcription-polymerase chain reaction, experimental lung metastasis models, and gelatin and fibrinogen/
plasminogen zymography to study the molecular mechanism of metastatic activities in MCF-7/DOX cells.
Results: We found that MCF-7/DOX acquired invasive activities. In addition, Western blot analysis showed
increased expression of epidermal growth factor receptor (EGFR) and Cox-2 in MCF-7/DOX cells. Inhibition of Cox-2,
phosphoinositide 3-kinase (PI3K)/Akt, or mitogen-activated protein kinase (MAPK) pathways effectively inhibited the
invasive activities of MCF-7/DOX cells. Gelatin and fibrinogen/plasminogen zymography analysis showed that the
enzymatic activities of matrix metalloproteinase-2 (MMP-2), MMP-9, and urokinase-type plasminogen activator were
markedly higher in MCF-7/DOX cells than in the MCF-7 cells. In vitro invasion assays and mouse models of lung
metastasis demonstrated that MCF-7/DOX cells acquired invasive abilities. Using siRNAs and agonists specific for
prostaglandin E (EP) receptors, we found that EP1 and EP3 played important roles in the invasiveness of MCF-7/
DOX cells.
Conclusions: We found that the invasive activity of MCF-7/DOX cells is mediated by Cox-2, which is induced by
the EGFR-activated PI3K/Akt and MAPK pathways. In addition, EP1 and EP3 are important in the Cox-2-induced
invasion of MCF-7/DOX cells. Therefore, not only Cox-2 but also EP1 and EP3 could be important targets for
chemosensitization and inhibition of metastasis in breast cancers that are resistant to chemotherapy.
Background
Breast cancer is the most common malignancy and a
major cause of death among women in the Western
world [1]. Many anticancer agents, including 5-fluorour-
acil, cyclophosphamide, and monoclonal antibodies such
as trastuzumab, have shown efficacy in extending the
survival of breast cancer patients; however, the mechan-
isms by which these agents inhibit breast cancer pro-
gression are not clearly understood. Although many
promising anticancer agents have been developed and
show potential in preclinical trials, classic chemothera-
peutic agents such as doxorubicin are still widely used
in patients [2].
A major problem with the use of chemotherapy to
treat many cancers (including breast cancer) is intrinsic
or acquired drug resistance, which results in disease
recurrence and metastasis. Recent results from several
laboratories have investigated the mechanism by which
breast cancer cells become resistant to doxorubicin, as
well as the molecular profile of breast cancer cells that
are resistant to doxorubicin [3,4]. Bcl-xl is responsible
for acquisition of resistance to chemotherapeutic agents
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increased survival of breast cancer cells [5,6]. Further-
more, recent evidence has suggested that the ability of
tumor cells to acquire an aggressive phenotype may
result from accumulation of genetic alterations con-
ferred by extended survival [7,8].
Cox-2 is involved in the inflammatory response and its
expression is commonly upregulated in human cancers;
therefore, Cox-2 has been suggested to play a major role
in tumorigenesis [9,10]. Recent studies have reported
that Cox-2 plays a key role as a regulator of chemother-
apy resistance in cancer. Cox-2 expression has been
reported to be indicative of an aggressive breast cancer
phenotype that is resistant to doxorubicin [11]. For
example, drug-resistant cell lines that overexpress P-gly-
coprotein 170 (MDR1/Pgp170) also have significantly
upregulated Cox-2 expression, indicating a strong corre-
lation between Cox-2 expression and resistance to che-
motherapy in breast cancer cell lines [12]. In addition,
selective inhibition of Cox-2 suppresses the invasion
activity of oral squamous cells through downregulation
of a matrix metalloproteinase-2 (MMP-2)-activating
mechanism [13]. Cox-2 overexpression in human breast
cancer cells enhances their motility and invasiveness
[14]. Furthermore, Cox-2 overexpression in human
breast cancers correlates with several clinical parameters
that are characteristic of aggressive breast disease
[15,16]. Inhibitors that are selective for Cox-2 have been
developed as anti-inflammatory agents and also show
effective anticancer properties in breast cancer patients
at risk for disease recurrence. Furthermore, inhibition of
Cox-2 has a significant effect on the drug resistance and
metastatic potential of cancer cells [17]. Knocking down
Cox-2 using small interfering RNA (siRNA) or Cox-2
inhibitors suppresses cell growth and invasion and
enhances the chemosensitivity of cancers, including
breast cancer [18-20].
Several lines of evidence have suggested that metasta-
sis may be enhanced by an ability to resist apoptosis
and highly metastatic cancer cells exhibit greater survi-
val ability and resistance to apoptosis than poorly meta-
static cells [21,22]. Therefore, cancer cells may acquire
invasive and metastatic properties during the process of
becoming resistant, a mechanism that remains poorly
understood. To identify genes associated with the inva-
sive and metastatic activities of drug-resistant cells, we
analyzed changes in gene expression in doxorubicin-
resistant MCF-7 breast cancer cells (MCF-7/DOX) that
we established using DNA array analysis. We observed
invasive activities related to high expression of Cox-2 in
MCF-7/DOX cells.
Having identified Cox-2 as an important regulator of
the invasiveness of MCF-7/DOX cells, we next asked
which upstream pathway modulates the expression of
Cox-2 and how the invasive activities increased doxoru-
bicin-resistant cancer in this study.
Methods
Animals, cells, and materials
Female 6-week-old Balb/c nude mice were purchased
from Charles River Laboratories (Wilmington, MA,
USA). The human breast cancer cell lines MDA-MB-
231, MCF-7, and T-47D were obtained from the Ameri-
can Type Culture Collection (Manassas, VA, USA).
MCF-7/DOX cells were derived from MCF-7 cells by
continuous culture in the presence of doxorubicin
(Sigma-Aldrich, St. Louis, MO, USA) for more than 3
months. Exposure of MCF-7 cells to stepwise increasing
concentrations (0.1-1 μM) of doxorubicin resulted in
the selection of doxorubicin-resistant MCF-7/DOX cells.
Exposure to doxorubicin was terminated 4 days prior to
the experiments. Cells were cultured in Dulbecco’s mod-
ified Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) and penicillin/streptomycin
(Invitrogen, Grand Island, NY, USA). Cell culture inserts
incorporating polyethylene terephthalate membranes
(6.4-mm diameter, 8- μm pore size) and 24-well plates
for invasion assays were purchased from Costar (Cam-
bridge, MA, USA).
We obtained MTT [3-(4,5-dimethylthazol-2-yl)-2,5-
diphenyltetrazolium bromide] from Sigma-Aldrich. The
phosphoinositide 3-kinase (PI3K) inhibitor LY294002
and mitogen-activated protein kinase (MAPK) inhibitor
U0126 were purchased from Calbiochem-Novabiochem
(La Jolla, CA, USA). Sulprostone, 17-phenyl trinor Pros-
taglandin E2 (17-PT-PGE2), Prostaglandin E2 (PGE2),
and the Cox-2 inhibitor NS398 were purchased from
Cayman Chemical (Ann Arbor, MI, USA). Epidermal
g r o w t hf a c t o r( E G F )w a sp u r c h a s e df r o mR & DS y s t e m s
Inc. (Minneapolis, MN, USA). Gefitinib was purchased
from Biaffin GmbH & Co KG (Kassel, Germany). Gela-
tin, fibrinogen, and plasminogen were obtained from
Sigma-Aldrich. Antibodies against ERK1, Cox-2, and
actin were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Antibodies against the EGF
receptor (EGFR), pAkt, Akt, phosphorylated extracellular
signal regulated kinase 1/2 (pERK1/2), pEGFR, poly
(ADP-ribose) polymerase (PARP), and tubulin were pur-
chased from Cell Signaling Technology (Danvers, MA,
USA). Doxorubicin was purchased from Sigma-Aldrich
and dissolved in phosphate-buffered saline (PBS) at var-
ious concentrations to establish dose responses. Syn-
thetic siRNAs targeting EGFR, prostaglandin E receptor
1 (EP1), and EP3 were purchased from Bioneer (Seoul,
Korea) and have the following sequences: EGFR (5’-
GGCACGAGUAACAAGCUCA-3’); EP1 (5’-GUCG-
GUAUCAUGGUGGUGU-3’); and EP3 (5’-GUCAUC-
GUCGUGUACCUGU-3’).
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The inhibitory effect of doxorubicin, the Cox-2 inhibitor
NS398, and the PI3K inhibitor LY294002 on growth of
MCF-7 and MCF-7/DOX cell lines was determined
using the MTT assay. Cells were plated onto 96-well
plates (3 × 10
3 cells/well) and cultured in medium with
or without various concentrations of doxorubicin,
NS398, LY294002, gefitinib, and U0126. The cells then
were grown for an additional total incubation of 24 or
72 h.
Flow cytometry assay
Cells were harvested, washed, fixed with paraformalde-
hyde and 70% ethanol, and stained using an APO-
BRDU kit (Biovision, Inc., Mountain View, CA, USA)
according to the manufacturer’s protocol. Flow cyto-
metric analysis was performed using a BD FACS Calibur
flow cytometer (BD Biosciences, San Jose, CA, USA)
equipped with a 488-nm argon-ion laser. Approximately
10,000 events (cells) were evaluated for each sample.
Western blot analysis
Total cell extracts were prepared from human breast
cancer cells treated with various drugs as indicated. Pre-
paration of whole-cell lysates, protein quantification, gel
electrophoresis, and Western blotting were performed
as described elsewhere [23]. Protein concentrations were
measured using the bicinchoninic acid protein assay
(Pierce Biotechnology, Rockford, IL, USA), as described
in the manufacturer’s protocol. Equivalent amounts of
protein from cell lysates or conditioned media (CM)
from each treatment group were resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and immunoblotted with primary antibodies.
Bands were detected using ECL Western blotting detec-
tion reagents from GE Healthcare (Chalfont St. Giles,
United Kingdom).
Invasion assays
In vitro invasion assays were performed as described else-
where [24]. Briefly, CM obtained by culturing Wi38 fibro-
blasts for 18 h in DMEM with 10% FBS was placed into
the lower chamber of each well as a chemoattractant. The
upper chamber contained 1 × 10
5 MCF-7/DOX cells incu-
bated in media alone or in the presence of NS398,
LY294002, gefitinib, or U0126 for 18 h. Cells were fixed
and stained with hematoxylin and eosin. Filters were cut
out and mounted on glass slides for cell counting. Cells
from the entire membrane field were counted. All experi-
ments were repeated at least three times.
siRNA transfection
MCF-7/DOX cells were transfected with siRNA using
Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA,
USA). The siRNA-transfected cells were incubated for
48 h and harvested for Western blot analysis.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated from MCF-7/DOX cells using
Trizol reagent (Invitrogen). cDNAs synthesized from 1
μg of total RNA were used as templates in a 50- μl reac-
tion using the TaqMan RT reagents according to the
manufacturer’s protocol (Applied Biosystems, Foster
City, CA). RT-PCR was performed to amplify genes
using a cDNA template corresponding to gene-specific
primer sets. The primer sequences used are as follows:
EP1 (forward 5’-TCGGCCTCCACCTTCTTTGGC-3’
and reverse 5’-CTGGCGCAGTAGGATGTACAC-3’),
EP2 (forward 5’-GTCATGTTCTCGGCCGGGGTG-3’
and reverse 5’-GAGGACTGAACGCATTAGTCT-3’),
EP3 (forward 5’- CGCCGGGAGAGCAAGCGCAAG-3’
and reverse 5’-GATGCGGCCCCACTGGGCACTGGA-
3’), EP4 (forward 5’-ATCTTACTCATTGCCACC-3’ and
reverse 5’-TCTATTGCTTTACTGAGCAC-3’), uroki-
nase-type plasminogen activator (uPA; forward 5’-
CCAATTAGGAAGTGTAAGCAGC-3’ and reverse 5’-
GCCAAGAAAGGGACATCTATG-3’), MMP-2 (forward
5’-TCGCCCATCATCAAGTTC-3’ and reverse 5’-
GTGATCTGGTTCTTGTCC-3’), MMP-9 (forward 5’-
AACCAATCTCACCGACAG-3’ and reverse 5’-
CAAAGGCGTCGTCAATCA-3’), b-actin (forward 5’-
GTGGGGCGCCCCAGGCACCA-3’ and reverse 5’-CTC
CTTAATGTCACGCACGATTTC-3’).
To avoid amplifying genomic DNA, gene primers were
chosen from different exons. PCR was performed in a
total reaction volume of 25 μlt h a tc o n t a i n e d2μlo f
cDNA solution and 0.2 μM of sense and antisense pri-
mers. The RT-PCR exponential phase was determined
on cycles 28-33 to allow quantitative comparisons
among the cDNAs amplified from identical reactions.
The amplification products (8 μL) were resolved on a
2% agarose gel, stained with ethidium bromide, and
visualized on a transilluminator and photographed.
Experimental lung metastasis models
MCF-7 and MCF-7/DOX cells (3 × 10
6 cells in 100 μL
PBS) were injected into the tail vein of Balb/c nude mice
( M C F - 7 ,n=8 ;M C F - 7 / D O X ,n=9 ) .T h r e em o n t h sa f t e r
injection, the animals were killed by CO2 inhalation and
their lungs were excised. Lung tumor formation was
observed and tumor nodules were counted under a dis-
secting microscope. All animal experiment procedures
were approved by the Institutional Animal Care and Use
Committee in Korea National Cancer Center.
Gelatin and fibrinogen/plasminogen zymography
The proteolytic activity of MMP-2, MMP-9, and uPA in
CM was analyzed by substrate-gel electrophoresis [25]
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0.12% (m/v) fibrinogen and plasminogen (0.01 NIH
unit/mL). CM from each treatment group was concen-
trated using an Amicon Ultra-4 centrifugal device (Milli-
pore, Bedford, MA, USA) and loaded onto gels. After
electrophoresis, the gels were washed with 2.5% Triton
X-100 and incubated overnight in zymogram incubation
buffer (50 mM Tris-HCl, 0.15 M NaCl, 10 mM CaCl2,
and 0.02% NaN3) at 37°C. Clear bands indicative of gela-
tinolytic activity were visualized by staining the gels with
Coomassie blue.
Gene expression analyses from whole genome
Total RNA was isolated and purified from MCF-7 and
MCF-7/DOX cells using the TRIzol reagent (Invitro-
gen) and RNease Mini kit (QIAGEN). Of those, 500 ng
RNA was biotinylated and amplified using the Illumina
TotalPrep RNA Amplification Kit (Ambion, TX)
according to the manufacturer’s instructions. The
cRNA yield was measured using RiboGreen RNA
quantitation kit (Invitrogen), and 750 ng of the cRNA
sample was hybridized on a human HT-12 expression
bead chip (Illumina, CA) for profiling 48,804 tran-
scripts per sample. Bead chips were stained with strep-
tavidin and scanned using an Illumina BeadArray
Reader. BeadStudio V3 was used to quantile-normalize
the data.
To find doxorubicin-resistant phenotype associated
genes, we applied expression data to search and include
genes with significant difference in expression levels
between MCF-7 and MCF-7/DOX. Gene sets with 2-
fold or more difference in mRNA level and p value cut-
off (0.05) are presented in Table 1.
Statistical analysis
The effect of doxorubicin or NS398 on breast cancer
cell proliferation was analyzed using one-way ANOVA
followed by Turkey’s multiple test (SPSS version 10;
SPSS, Chicago, IL, USA). The data of in vitro cancer cell
invasion and tumor incidence in the mice were analyzed
using Student’s t-test (Microsoft Excel software version
2007; Microsoft Corporation).
Results
Resistance of MCF-7/DOX cells to doxorubicin
Doxorubicin is one of the most commonly used drugs in
the treatment of cancer, but its inhibitory effect on cell
proliferation varies in several cancer cell lines. Therefore,
we investigated whether doxorubicin has the same anti-
proliferative effect in MDA-MB-231, MCF-7, MCF-7/
DOX, and T-47D cell lines. The cells were treated with
the indicated concentrations of doxorubicin for 72 h and
cell proliferation was measured using the MTT assay.
Doxorubicin inhibited cell proliferation in a concentra-
tion-dependent manner in MCF-7 and T47D cells, and
to a lesser extent in MDA-MB-231 cells. By contrast,
doxorubicin-mediated inhibition was significantly
reduced in MCF-7/DOX cells (Figure 1A). We next mea-
sured the growth of MCF-7 and MCF-7/DOX cells at
lower doxorubicin concentrations and MCF-7/DOX cells
were consistently resistant to doxorubicin (Figure 1B).
We then tested whether the doxorubicin-mediated
growth inhibition was mediated by apoptosis. After
MCF-7 and MCF-7/DOX cells were treated with 1 μM
doxorubicin for 48 h, terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick end labeling-based fluores-
cence-activated cell sorting analysis showed that
doxorubicin did not induce apoptosis in MCF-7/DOX
cells; however, doxorubicin did induce apoptosis in
MCF-7 cells (Figure 1C). We further confirmed the
resistance of MCF-7/DOX cells to doxorubicin by Wes-
tern blot analysis. Induction of PARP cleavage (a marker
of apoptosis) in MCF-7 cells confirmed that doxorubicin
induced apoptosis in these cells. However, PARP was
not cleaved in MCF-7/DOX cells treated with doxorubi-
cin (Figure 1D).
Acquisition of invasive and metastatic properties in MCF-
7/DOX cells
Intrinsic or acquired drug resistance results in disease
recurrence and metastasis [26]. We analyzed changes in
gene expression in doxorubicin-resistant MCF-7/DOX
cells using DNA array analysis. Differentially expressed
genes related with invasion are listed in Table 1.
We next examined whether MCF-7/DOX cells
acquired metastatic properties. First, we measured the
enzymatic activities of MMP-9, MMP-2, and uPA in
MCF-7 and MCF-7/DOX cells by gelatin and fibrino-
gen/plasminogen zymography. The enzymatic activities
of MMP-2, MMP-9, and uPA were markedly higher in
MCF-7/DOX cells than in non-invasive MCF-7 cells
(Figure 2A). Increased levels of MMP-9 and MMP-2
expression have been correlated with an invasive pheno-
type of cancer cells [27]. Thus, we assessed the invasive-
ness of MCF-7 and MCF-7/DOX cells using in vitro
invasion assays. As expected, the MCF-7/DOX cells
were significantly more invasive than MCF-7 cells
Table 1 Differentially requlated genes in MCF-7/DOX cells
Gene symbol Name Fold change
EGFR Epidermal growth factor receptor 19.079
TWIST1 Twist transcription factor 8.661
MMP9 Matrix metallopeptidase 9 5.890
PLAU Plasminogen activator, urokinase 159.280
TIMP3 TIMP metallopeptidase inhibitor3 0.020
CDH2 N-cadherin 94.160
CDH1 E-cadherin 0.001
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cells in vivo, we developed a breast cancer model of
lung metastasis. Three months after injecting MCF-7/
DOX cells through the tail veins of balb/c nude mice,
the mice were killed, and the total number of visible
lung tumor nodules per mouse was quantified under a
stereomicroscope. Lung tumor nodules were present in
the mice injected with MCF-7/DOX cells, while no
mouse injected with MCF-7 cells had lung metastases
(Figure 2C and 2D). These results suggest that MCF-7
cells obtained metastatic abilities after acquiring resis-
tance to doxorubicin.
Cox-2 mediates invasiveness of MCF-7/DOX cells
Recent studies have reported that Cox-2 plays a key role as
a regulator of chemotherapy resistance in cancer [28]. In
addition, Cox-2 expression plays an important role in the
metastatic and invasive abilities of cancer cells [29]. Selec-
tive inhibition of Cox-2 was shown to suppress the inva-
sion of oral squamous cells by downregulating an MMP-
2-activating mechanism [13]. Therefore, we tested whether
invasiveness of MCF-7/DOX cells is related to Cox-2
expression. Western blot analysis showed a high basal
level of Cox-2 in doxorubicin-resistant MCF-7/DOX cells
and metastatic MDA-MB-231 cells (Figure 3A).
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Figure 1 Resistance to doxorubicin in MCF-7/DOX cells.( A, B) Cell proliferation in MDA-MB-231, MCF-7, MCF-7/DOX, and T-47D breast
cancer cells 72 h after treatment with doxorubicin at (A) high or (B) low concentration. (C) The number of apoptotic cells was counted by
terminal deoxynucleotidyl transferase dUTP nick end labeling-based fluorescence-activated cell sorting analysis 48 h after doxorubicin treatment.
(D) Western blot analysis of MCF-7 and MCF-7/DOX cells following treatment with doxorubicin for 48 h. Values shown are means ± standard
deviation (SD). *P < 0.01; **P < 0.001 compared with the untreated group.
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sing cells (MCF-7/Cox-2) demonstrate increased inva-
siveness [30]. Moreover, several studies have suggested
that targeting Cox-2 may protect against development
of invasive breast cancer [17-19]. Thus, we tested the
effects of a Cox-2 inhibitor on invasion of MCF-7/DOX
cells. Treatment of MCF-7/COX cells with the Cox-2
inhibitor NS398 decreased their invasive potential (Fig-
ure 3B), indicating that Cox-2 expression contributes to
the invasive activity of MCF-7/DOX cells. We next
determined the effects of the Cox-2 inhibitor NS398 on
activities of MMP-9, MMP-2, and uPA secreted from
MCF-7/DOX cells using plasminogen/fibrinogen and
gelatin zymography assays. We found that the activity of
MMP-9 and uPA was inhibited by 50 μM NS398, a con-
centration that did not affect MCF-7/DOX cell prolif-
eration (Figure 3C and 3D). The effect of Cox-2
expression on invasiveness of MCF-7/DOX cells was
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Figure 2 Acquisition of invasive and metastatic properties by MCF-7/DOX cells.( A) The activity of MMP-2, MMP-9, and uPA in MCF-7 and
MCF-7/DOX cells was determined by gelatin or fibrinogen/plasminogen zymography. (B) An invasion assay was performed with MCF-7 and
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Consistent with the results of the Cox-2 inhibitor
experiment, transfection of siRNA targeting Cox-2 sup-
pressed migration of MCF-7/DOX cells in an in vitro
migration assay (Figure 3E).
Effect of the EGFR pathway on Cox-2-mediated invasion
of MCF-7/DOX cells
Having identified Cox-2 as an important regulator of
invasiveness of MCF-7/DOX cells, we next asked which
upstream pathway modulates the expression of Cox-2 in
this cell line. Because EGFR has been reported to regu-
late Cox-2 expression [31], we hypothesized that activa-
tion of the EGFR pathway may induce Cox-2
expression. First, we examined the basal expression level
of EGFR in a subset of breast cancer cell lines. Western
blot analysis showed high levels of EGFR expression in
the doxorubicin-resistant MCF-7/DOX and MDA-MB-
231 cells, which were invasive and had elevated Cox-2
expression (Figure 4A).
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Figure 4 Effect of the EGFR pathway on Cox-2 mediated invasiveness of MCF-7/DOX cells.( A) Western blot analysis of EGFR expression in
MDA-MB-231, MCF-7, MCF-7/DOX, and T-47D cells. (B) Western blot analysis of MCF-7/DOX and MDA-MB-231 cells that were transfected with
control or EGFR siRNA. (C) Western blots of lysates from MCF-7/DOX cells treated with EGF (100 ng/mL) for the indicated times (0-12 h). (D)
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with 2 μM gefitinib for 24 h. *P < 0.01 (t-test).
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Page 8 of 13We next tested the role of the EGFR pathway on
induction of Cox-2 expression by treating cells with
EGF and blocking these pathways using EGFR-specific
siRNA. Cox-2 expression was markedly suppressed
when both MCF-7/DOX and MDA-MB-231 cells were
transfected with EGFR-specific siRNAs (Figure 4B). In
addition, Western blot analyses of MCF-7/DOX cells
revealed that Cox-2 expression was induced within 2 h
of EGF treatment (Figure 4C). We further confirmed
that blocking the EGFR pathway suppressed Cox-2
expression using a selective EGFR tyrosine kinase inhibi-
tor, gefitinib. Treating cells for 24 h with gefitinib effec-
tively suppressed EGF-induced Cox-2 expression in
MCF-7/DOX cells (Figure 4D). We then tested the
effects of the EGFR inhibitor on invasion of MCF-7/
DOX cells. Gefitinib decreased the invasive potential of
MCF-7/DOX cells (Figure 4E), indicating that EGFR
contributes to invasiveness of MCF-7/DOX cells by
upregulating Cox-2.
Effect of EGFR on PI3K/Akt- and MAPK-mediated Cox-2
expression in MCF-7/DOX cells
Because EGFR controls several other pathways, such as
the PI3K/Akt and MAPK pathways [32,33], we next
investigated which downstream pathway was involved in
EGFR-mediated Cox-2 expression. As expected, treating
MCF-7/DOX cells with EGF for 8 h to induce Cox-2
expression activated both the PI3K/Akt and MAPK
pathways (Figure 5A). To confirm the role of the PI3K/
Akt and MAPK pathways in Cox-2 expression, we stu-
died the effect of the PI3K/Akt inhibitor LY294002 and
the MAPK inhibitor U0126 on EGF-induced expression
of pAkt and Cox-2 in MCF-7/DOX cells. Western blot
analysis showed that LY294002 and U0126 dramatically
suppressed activation of pAkt and pERK1/2, respec-
tively, and downregulated EGF-induced Cox-2 expres-
sion (Figure 5B). To investigate the role of the PI3K/Akt
pathway in invasiveness of MCF-7/DOX cells, we deter-
mined whether blocking the PI3K/Akt pathway would
inhibit invasion of MCF-7/DOX cells in an in vitro inva-
sion assay. Blocking the PI3K/Akt pathway with
LY294002 or the MAPK pathway with U0126 dramati-
cally inhibited invasion of MCF-7/DOX cells, but did
not affect proliferation of the cells (Figure 5C and 5D).
B e c a u s ew ew o n d e r e dw h e t h e rP I 3 K / A k to rM A P Ks i g -
naling alone not through Cox-2/PGE2 can increase
expression of MMP-2, MMP-9, and uPA, we tested
MMP-2, MMP-9, and uPA mRNA expression in MCF-
7/DOX cells transfected with siRNA specific for Cox-2
(Figure 5E). Transfection with siRNAs targeting Cox-2
specifically inhibited MMP-2, MMP-9, or uPA RNA
expression in MCF-7/DOX cells, whereas control
scrambled siRNA demonstrated no effect (Figure 5F).
Expression of MMP-2, MMP-9 and uPA mRNA was
suppressed by the PI3K/Akt inhibitor LY294002 and the
MAPK inhibitor U0126 in MCF-7/DOX cells transfected
with control siRNA; however, their expressions were less
affected by either LY294002 or U0126 in MCF-7/DOX
cells transfected with Cox-2 siRNA (Figure 5F).
Role of EP1 and EP3 receptors in Cox-2 mediated
invasion of MCF-7/DOX cells
PGE2, which is produced by Cox-2, exerts its effect by
binding to specific prostanoid receptors (EP1, EP2, EP3,
and EP4), which are a family of G-protein-coupled
receptors [34]. Thus, we investigated the role of EP
receptors in the Cox-2-mediated invasion in MCF-7/
DOX cells. First, we compared the basal expression
levels of the EP receptors in MCF-7 and MCF-7/DOX
cells by RT-PCR. We found that EP1 and EP3 mRNAs
were upregulated, while EP2 and EP4 mRNAs were
downregulated in MCF-7/DOX cells (Figure 6A). Simi-
larly, specific induction of EP1 and EP3 mRNA, but not
EP2 and EP4 mRNA was observed in MCF-7/DOX cells
treated with PGE2 for 24 h (Figure 6B). To determine
which EP receptor regulates invasive activities of MCF-
7/DOX cells, we blocked expression of either EP1 or
EP3 with gene-specific siRNAs and performed an inva-
sion assay. Invasive activities induced by PGE2 in MCF-
7/DOX cells were inhibited by suppression of either EP1
or EP3 expression (Figure 6C). We further confirmed
the effect of EP1 and EP3 on uPA, MMP-2, and MMP-9
expression by measuring the expression levels of uPA,
MMP-2, and MMP-9 after blocking EP1 and EP3
expression with gene-specific siRNAs. RT-PCR data
showed that expression of MMP-2 and MMP-9 were
reduced when expression of EP1 or EP3 was inhibited
(Figure 6D). To determine which EP receptor regulates
invasive activities of MCF-7/DOX cells, cells were trea-
ted with EP1- or EP3-specific agonists and MMP-2,
MMP-9 and uPA mRNA expression was examined by
RT-PCR. Only EP1/EP3 receptor or EP3 agonists signifi-
cantly increased MMP-2, MMP-9, and uPA mRNA
expression. Furthermore, treatment with the EP1 recep-
tor antagonist AH6809 effectively attenuated MMP-2,
M M P - 9 ,a n du P Am R N Ae x p r e s s i o nb yP G E 2 in MCF-
7/DOX cells (Figure 6E).
Discussion
Chemotherapy plays an important role in the treatment
of breast cancer; however, long-term treatment often
results in chemoresistance, leading to disease recurrence
and metastasis [18-20]. To study the molecular mechan-
isms underlying invasive and metastatic activities in
drug-resistant cancer cells, we generated the doxorubi-
cin-resistant MCF-7 breast cancer cell line MCF-7/
DOX. We found that MCF-7/DOX breast cancer cells
displayed enhanced metastatic and invasive behavior
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Page 11 of 13both in in vitro cell invasion assays and in vivo in a
mouse lung tumor model. We demonstrated that inva-
siveness of MCF-7/DOX cells resulted from Cox-2 acti-
vation, which was induced by either the EGFR-activated
PI3K/Akt or MAPK pathway. Inhibiting either Cox-2 or
the PI3K/Akt pathway effectively inhibited the invasive-
ness of MCF-7/DOX cells.
Cox-2 was coexpressed with EGFR in human colorec-
tal cancer and bronchial adenocarcinomas [35,36] and
induced in a human glioma cell line [31]. We investi-
gated the mechanisms by which EGFR signaling regu-
lates Cox-2 expression. The EGFR pathway controls
several pathways, including the PI3K/Akt and MAPK
pathways [32]. Our data showed that, in MCF-7/DOX
cells, Cox-2 expression was regulated by both the PI3K/
Akt and Ras/Raf/MAPK pathways through EGFR signal-
ing. Western blot analysis showed that, in MCF-7/DOX
and MDA-MB-231 cells, Cox-2 expression was reduced
when EGFR expression was blocked by an EGFR-specific
siRNA. In addition, the EGFR inhibitor gefitinib signifi-
cantly suppressed EGF-induced Cox-2 expression and
invasion of MCF-7/DOX cells. These data provide evi-
dence that Cox-2 expression induced by the EGFR path-
way is associated with invasiveness of MCF-7/DOX cells.
PGE2, the major end product of Cox-2 activation, is
also known to activate EGFR through various pathways
[37]. Therefore to clarify whether PGE2 signaling
through EPs promotes the PI3K/Akt or MAPK pathway-
mediated invasion primarily, we evaluated the effect of
EP1- or EP3-specific agonists or EP inhibitor on the
PI3K/Akt or MAPK pathways, but we found that PGE2
signaling through EPs didn’t affect PI3K/Akt and MAPK
pathway in the MCF-7/DOX cells (data not shown).
Recent studies have shown that Cox-2 mRNA and
protein expression in several cancer cell lines are regu-
lated by the insulin-like growth factor (IGF)-1R/PI3K
and nuclear factor-kappa B/nuclear factor of kappa light
polypeptide gene enhancer in B-cells inhibitor pathways
[38,39]. In addition to the PI3K/Akt pathway, the Ras/
Raf/MAPK pathway is also a downstream transducer of
IGF-1R signaling. The IGF-1R signaling pathway plays a
major role in cell proliferation, apoptosis, invasion, and
angiogenesis. Moreover, IGF-1R has been shown to
upregulate Cox-2 mRNA expression and PGE2 synthesis
in cancer cells [40]. Although we found that IGF-1R
expression was neither increased nor constitutively acti-
vated in MCF-7/DOX cells, activation of the IGF-1R
pathway may still contribute to Cox-2 expression and
our efforts are ongoing to determine any further
possibility.
Treating cells with EGF also increased pAkt and
pERK1/2 expression in MCF-7/DOX cells. To investi-
gate the role of the PI3K/Akt pathway in Cox-2 expres-
sion, we studied the effect of the PI3K/Akt inhibitor
LY294002 on EGF-induced pAkt and Cox-2 expression.
Western blot analysis showed that LY294002 dramati-
cally suppressed pAkt activation and Cox-2 expression
induced by EGF in MCF-7/DOX cells.
Because Cox-2 exerts its effects by producing PGE2,
which binds to specific EP receptors [34], we investi-
gated the role of specific EP receptors in Cox-2-
mediated invasion of MCF-7/DOX cells. PGE2 treatment
induced expression of the EP1 and EP3 receptors, sug-
gesting that these two receptors are likely involved in
the invasiveness by MCF-7/DOX cells. Both EP1 and
EP3 receptors played an important role in Cox-2
induced invasion of MCF-7/DOX cells. We showed that
selective inhibition of EP1 and EP3 using siRNAs inhib-
ited PGE2-induced invasion of MCF-7/DOX cells, as
well as expression of MMP-2 and MMP-9. A previous
study showed increased Cox-2 expression in patients
with poorly differentiated breast cancer and poor clinical
outcomes for patients treated with doxorubicin [11].
However, the expression pattern of EP receptors has
never been studied in breast cancer. Therefore, our find-
ings are the first to suggest a pivotal role for the EP1
and EP3 receptors in doxorubicin-resistant breast cancer
cells.
Conclusions
Together, we have demonstrated that invasiveness of
MCF-7/DOX cells results from Cox-2 activation, which
is induced by either the EGFR-activated PI3K/Akt or
MAPK pathway. Inhibiting Cox-2 or the EGFR pathway
effectively inhibited invasiveness of MCF-7/DOX cells.
We also found that the EP receptors EP1 and EP3 are
important for Cox-2-induced invasion of MCF-7/DOX
cells. Therefore, not only Cox-2 but also EP1 and EP3
could be important targets for chemosensitizing and
inhibiting metastasis in chemotherapy-resistant breast
cancers.
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